on February 2, 2006
Published online before print February 2, 2006, doi: 10.1161/01.ATV.0000208363.85388.8f
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 1, 2005
Accepted on December 23, 2005
Comparison of Circulating Adiponectin and Proinflammatory Markers Regarding Their Association With Metabolic Syndrome in Japanese Men
Kunihiro Matsushita ;
From the Departments of Cardiology (K.M., K.S., T.K., T.M.), Public Health/Health Information Dynamics (H.Y., K.T., K.W., R.O., H.T.), and Metabolic Diseases (S.T.), Nagoya University Graduate School of Medicine, Japan.
* To whom correspondence should be addressed. E-mail: toyosima{at}med.nagoya-u.ac.jp.
Background--Anti-inflammatory and proinflammatory molecules purportedly play an important role in developing metabolic syndrome (MetS). However, little is known as to the relative importance of these molecules in the association with MetS.
Methods and Results--We studied 624 middle-aged Japanese men without medical history of cardiovascular disease or cancer and investigated the associations of circulating tumor necrosis factor-
(TNF-), interleukin-6 (IL-6), C-reactive protein (CRP), and adiponectin with MetS. We used the respective definitions proposed by the National Cholesterol Education Program Adult Treatment Panel III (ATP-III), the International Diabetes Federation, and the Japanese Society of Internal Medicine. Decreased serum adiponectin was observed in those with any of the ATP-III-MetS components, whereas this was not the case with increased TNF-, IL-6, or CRP. Adiponectin and CRP levels linearly deteriorated with an increasing number of ATP-III-MetS components (trend P<0.001, respectively). Significantly higher CRP and lower adiponectin levels were observed in those who met any MetS criteria, whereas increased TNF- was observed in only those with ATP-III-MetS. Finally, odds ratios (ORs) for MetS prevalence of a 1-SD increase/decrease in log-transformed 4 markers were calculated with multivariate logistic regression analyses. Consequently, decreased adiponectin was associated most strongly with ATP-III-MetS (adiponectin: OR, 1.90 [95% CI, 1.44 to 2.51]; P<0.001; CRP: OR, 1.33 [95% CI, 1.01 to 1.74]; P=0.03; TNF-: OR, 1.25 [95% CI, 0.94 to 1.67]; P=0.12; and IL-6: OR, 0.87 [95% CI, 0.63 to 1.19]; P=0.37). This result was not altered by using the other 2 criteria.
Conclusions--The present results raise the possibility that decreased serum adiponectin might be fundamentally involved in the development of MetS.
Key words: cardiovascular disease prevention • inflammation • metabolic syndrome • risk factors
This article has been cited by other articles:
 |
|
 |
|
  Y. Liu, S. Chewchuk, C. Lavigne, S. Brule, G. Pilon, V. Houde, A. Xu, A. Marette, and G. Sweeney Functional significance of skeletal muscle adiponectin production, changes in animal models of obesity and diabetes, and regulation by rosiglitazone treatment Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E657 - E664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Deepa and L. Q. Dong APPL1: role in adiponectin signaling and beyond Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E22 - E36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rao, L. Li, H. Tighiouart, B. L. Jaber, B. J. G. Pereira, V. S. Balakrishnan, and the HEMO Study Group Plasma adiponectin levels and clinical outcomes among haemodialysis patients Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2619 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-F. Hivert, L. M. Sullivan, C. S. Fox, D. M. Nathan, R. B. D'Agostino Sr., P. W. F. Wilson, and J. B. Meigs Associations of Adiponectin, Resistin, and Tumor Necrosis Factor-{alpha} with Insulin Resistance J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3165 - 3172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. You, B. J. Nicklas, J. Ding, B. W. J. H. Penninx, B. H. Goodpaster, D. C. Bauer, F. A. Tylavsky, T. B. Harris, S. B. Kritchevsky, and for the Health, Aging and Body Composition Study The Metabolic Syndrome Is Associated With Circulating Adipokines in Older Adults Across a Wide Range of Adiposity J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2008; 63(4): 414 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Gabler and M. E. Spurlock Integrating the immune system with the regulation of growth and efficiency J Anim Sci, April 1, 2008; 86(14_suppl): E64 - E74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tabara, H. Osawa, R. Kawamoto, R. Tachibana-Iimori, M. Yamamoto, J. Nakura, T. Miki, H. Makino, and K. Kohara Reduced High-Molecular-Weight Adiponectin and Elevated High-Sensitivity C-Reactive Protein Are Synergistic Risk Factors for Metabolic Syndrome in a Large-Scale Middle-Aged to Elderly Population: the Shimanami Health Promoting Program Study J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 715 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Okamoto, E. J. Folco, M. Minami, A.K. Wara, M. W. Feinberg, G. K. Sukhova, R. A. Colvin, S. Kihara, T. Funahashi, A. D. Luster, et al. Adiponectin Inhibits the Production of CXC Receptor 3 Chemokine Ligands in Macrophages and Reduces T-Lymphocyte Recruitment in Atherogenesis Circ. Res., February 1, 2008; 102(2): 218 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M.J. Wassink, Y. van der Graaf, J. K. Olijhoek, F. L.J. Visseren, and for the SMART Study Group Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm Eur. Heart J., January 2, 2008; 29(2): 213 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, R. Retnakaran, A. Hanley, R. Tungtrongchitr, C. Shaw, and G. Sweeney Total and High Molecular Weight But Not Trimeric or Hexameric Forms of Adiponectin Correlate with Markers of the Metabolic Syndrome and Liver Injury in Thai Subjects J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4313 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mitsuhashi, H. Yatsuya, K. Tamakoshi, K. Matsushita, R. Otsuka, K. Wada, K. Sugiura, S. Takefuji, Y. Hotta, T. Kondo, et al. Adiponectin Level and Left Ventricular Hypertrophy in Japanese Men Hypertension, June 1, 2007; 49(6): 1448 - 1454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schillaci and M. Pirro Hypoadiponectinemia: A Novel Link Between Obesity and Hypertension? Hypertension, June 1, 2007; 49(6): 1217 - 1219. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Y. Bang, J. L. Saver, B. Ovbiagele, Y. J. Choi, S. R. Yoon, and K. H. Lee Adiponectin levels in patients with intracranial atherosclerosis Neurology, May 29, 2007; 68(22): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Q. Shaibi, M. L. Cruz, M. J. Weigensberg, C. M. Toledo-Corral, C. J. Lane, L. A. Kelly, J. N. Davis, C. Koebnick, E. E. Ventura, C. K. Roberts, et al. Adiponectin Independently Predicts Metabolic Syndrome in Overweight Latino Youth J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1809 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-Y. Liu, J.-H. Chen, L.-J. Lin, and J. K. Liao Increased Rho Kinase Activity in a Taiwanese Population With Metabolic Syndrome J. Am. Coll. Cardiol., April 17, 2007; 49(15): 1619 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Donahue, K. Rejman, L. B. Rafalson, J. Dmochowski, S. Stranges, and M. Trevisan Sex Differences in Endothelial Function Markers Before Conversion to Pre-Diabetes: Does the Clock Start Ticking Earlier Among Women?: The Western New York Study Diabetes Care, February 1, 2007; 30(2): 354 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Winer, T. L. Zern, S. E. Taksali, J. Dziura, A. M. G. Cali, M. Wollschlager, A. A. Seyal, R. Weiss, T. S. Burgert, and S. Caprio Adiponectin in Childhood and Adolescent Obesity and Its Association with Inflammatory Markers and Components of the Metabolic Syndrome J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4415 - 4423. [Abstract] [Full Text] [PDF]
|
|